Durvalumab + Targeted Therapies in Advanced Urothelial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
An Adaptive, Biomarker-Directed Platform Study of Durvalumab in Combination With Targeted Therapies in Advanced Urothelial Cancer
Nat. Med. 2021 May 01;27(5)793-801, T Powles, D Carroll, S Chowdhury, G Gravis, F Joly, J Carles, A Fléchon, P Maroto, D Petrylak, F Rolland, N Cook, AV Balar, SS Sridhar, MD Galsky, P Grivas, A Ravaud, R Jones, J Cosaert, D Hodgson, I Kozarewa, R Mather, R McEwen, F Mercier, D LandersFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.